
Arbutus Biopharma Showcases Promising Hepatitis B Research at EASL Congress
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) announced the acceptance of five abstracts, including a late-breaking study, for presentation at the European Association for the Study of the Liver …
Arbutus Biopharma Showcases Promising Hepatitis B Research at EASL Congress Read More